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Abstract
Background—We have previously defined a parkinsonism-related metabolic brain network in 
rhesus macaques using a high-resolution research PET camera. This brief article reports a 
descriptive pilot study to assess the reproducibility of network activity and regional glucose 
metabolism in independent parkinsonian macaques using a clinical PET/CT camera.
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Methods—[18F]fluorodeoxyglucose PET scans were acquired longitudinally over three months 
in three drug-naïve parkinsonian and three normal cynomolgus macaques. Group difference and 
test-retest stability in network activity and regional glucose metabolism were evaluated 
graphically using all brain images from these macaques.
Results—Comparing the parkinsonian macaques to the controls, network activity was elevated 
and remained stable over three months. Normalized glucose metabolism increased in putamen/
globus pallidus and sensorimotor regions, but decreased in posterior parietal cortices.
Conclusions—Parkinsonism-related network activity can be reliably quantified in different 
macaques with a clinical PET/CT scanner and is reproducible over a time period typically 
employed in preclinical intervention studies. This measure can be a useful biomarker of disease 
process or drug effects in primate models of Parkinson’s disease.
Keywords
Parkinson’s disease; animal models; glucose metabolism; position emission tomography; brain 
imaging biomarker
Introduction
PET imaging of functional brain network activity may provide a valuable biomarker 
applicable to both preclinical studies in animals and translational research in humans. This 
methodology can potentially identify novel mechanisms of disease process and define 
mechanisms and extent of drug action. Using high resolution PET with 
[18F]fluorodeoxyglucose (FDG) and brain network analysis, we have previously reported 
spatial covariance patterns of abnormal regional glucose metabolism in patients with 
Parkinson’s disease (PD)1 and in non-human primates (NHPs) following 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration2. In both PD patients and MPTP-
lesioned rhesus macaques, this parkinsonism-related pattern (PRP) was characterized by 
hypermetabolism in the putamen/globus pallidus, thalamus, pons and sensorimotor cortex, 
covarying with hypometabolism in the posterior parietal-occipital cortices. PRP network 
expression in individual subjects was found to be abnormally elevated in PD patients or 
parkinsonian macaques, correlated with the severity of motor symptoms and sensitive for 
assessing treatment responses to novel experimental therapies in clinical trials3 and in a 
preclinical setting4.
PRP networks have been defined consistently using FDG images acquired in multiple 
cohorts of PD patients on different PET scanners5–8. Although PRP network was found to 
be reproducible in two separate cohorts of MPTP-lesioned rhesus macaques (Macaca 
mulatta) imaged on the same high resolution research tomography (HRRT)2, it is currently 
unknown whether this network can be reliably quantified in a different species of 
parkinsonian macaques scanned on a lower resolution clinical tomography. Moreover, the 
test-retest reliability of PRP expression demonstrated in PD patients1 has not been evaluated 
in NHP models of PD.
In this descriptive pilot study we assessed (1) the network activity with a clinical PET/CT 
scanner in a previously untreated cohort of cynomolgus macaques undergoing systemic 
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MPTP administration; (2) the test-retest reproducibility of network activity in individual 
macaques over a time interval typically used in experimental therapeutic research with 
NHPs; (3) the effect of altered regional glucose metabolism on the stability of network 
activity in parkinsonian macaques. Our primary goal was to establish a viable methodology 
for accelerating biomedical advances in drug discovery based on common imaging 
biomarkers across both animals and humans.
Methods
Animal Preparation and Characteristics
This pilot study included six adult female cynomolgus macaques matched in age and weight 
(Macaca fascicularis, age 6.9 ± 0.5 [mean ± SD], range 6.2–7.5 years; weight 3.0 ± 0.2, 
range 2.7–3.3 kg). Three macaques exhibited stable MPTP-induced parkinsonism with 
moderate to marked levels of disability. Three others served as normal controls. Procedures 
of animal preparation, MPTP injection and behavioral testing have been fully described 
elsewhere9. All studies were performed with the regulatory approval (Suzhou IACUC, 
Jiangsu Province, China) and in accordance with the Guide for the Care and Use of 
Laboratory Animals (NIH, USA).
PET Imaging and Processing
FDG PET was performed at Huashan Hospital PET Center using a Siemens Biograph 64 
PET/CT camera with a resolution of 4~6 mm10. The animal was awake during uptake and 
rapidly anesthetized at 30 min following intravenous injection of 5 mCi of FDG. Three 
MPTP animals were scanned two weeks in advance as an initial trial. The three MPTP and 
three normal animals were then scanned at baseline and after three months. One normal 
animal did not complete the follow-up imaging because of the failure of anesthesia. All 
animals were scanned between 40–80 min post-injection using the same imaging protocol 
(Supplementary Table 1).
Image preprocessing was performed using the procedures described previously2. PET 
images were spatially normalized into a macaque brain template11 and smoothed with a 4 
mm Gaussian filter. This produced fourteen usable PET images of cerebral glucose 
metabolism: nine for the parkinsonian animals and five for the normal controls.
Measurement of PRP Expression and Regional Glucose Metabolism
PRP expression was assessed for the parkinsonism-related brain network (Fig. 1A) derived 
previously in a derivation sample of rhesus macaques2, using FDG PET images acquired on 
a HRRT human scanner with a superior 3D resolution of 2~3 mm12. Network scores were 
computed prospectively in multiple PET images from all cynomolgus macaques (i.e. 
validation sample) and converted into z-scores with respect to those in the derivation 
sample.
Normalized regional metabolic values were measured in the validation sample with a 
spherical volume of interest (3 mm in radius) centered in brain regions showing abnormal 
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metabolic activity in the PRP (Fig. 1A). The volumes were placed anatomically over all 
FDG PET scans in reference to a macaque brain atlas13.
Graphic Procedures
Because the sample size of the animals was small in this pilot study we could not perform 
any statistical analysis such as repeated-measures analysis of variance. Instead, we used a 
graphical approach to visualize group differences in network score or regional metabolism 
and their longitudinal changes over time. Measures from the repeat scans in each animal 
were combined and clearly marked in the corresponding graphs.
Results
Reproducibility of PRP Expression in Independent Macaques
PRP scores were elevated in the MPTP-lesioned animals compared to the normal controls in 
both the derivation sample and the validation sample (Fig. 1B; Supplementary Fig. 1). PRP 
scores were similar between the normal controls but mostly lower in the parkinsonian 
animals in the validation sample than those in the derivation sample.
Test-retest Reliability of PRP Expression
PRP scores in the validation sample showed excellent stability over a short period of two 
weeks in the three MPTP-lesioned animals and in the five test-retest animals over a longer 
period of three months (Fig. 1C).
Metabolic Differences between Parkinsonian and Normal Macaques
FDG PET images revealed relative metabolic differences between the MPTP-lesioned and 
the normal animals (Fig. 2; Supplementary Table 2). Normalized metabolism increased 
bilaterally in the putamen/globus pallidus (18–19%) and sensorimotor cortex (20–25%) with 
smaller increases in the right supplementary motor area (15%), but decreased bilaterally in 
the posterior parietal cortex with a smaller magnitude (11–13%). These measures were also 
stable over time in all animals (Supplementary Fig. 2).
Discussion
This descriptive pilot study compared brain network activity between two independent 
cohorts of MPTP-lesioned and normal macaques using FDG PET imaging. We found that 
PRP scores were elevated in parkinsonian macaques in both cohorts imaged on two different 
PET scanners (Fig. 1). Lower PRP scores in the validation sample reflected milder motor 
symptoms in the drug-naïve parkinsonian animals. These levels of reproducibility across the 
animal cohorts, species and the imaging instruments paralleled several previous reports in 
patients with PD5–8. Moreover, we demonstrated high test-retest reliability of network 
expression in the parkinsonian animals, also very similar to that obtained in PD patients 
scanned with FDG PET over an interval of two months1.
It is worth noting that the same PRP network previously identified in rhesus macaques can 
be detected in bilateral models of experimental parkinsonism produced in a different species 
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of NHPs, cynomolgus macaques. This is a major advantage given that both cynomolgus and 
rhesus macaques are commonly used in translational biomedical research. Furthermore, PRP 
expression can be determined on a prospective single-case basis using lower resolution 
clinical PET cameras that are more widely available.
We have also explored abnormal glucose metabolism in the parkinsonian cynomolgus 
macaques graphically (Fig. 2). Normalized metabolism was found to increase mainly in the 
key relay stations within the basal ganglia and the sensorimotor cortices, but decrease in the 
posterior parietal regions in the parkinsonian animals. The metabolic differences in these 
subcortical and cortical regions were more or less symmetrical in terms of anatomical 
distribution and magnitude, consistent with the predominantly bilateral motor symptoms 
seen in these macaques following MPTP administration.
It is this alteration in regional glucose metabolism that accounts for the observed differences 
in PRP scores between the parkinsonian and control cynomolgus macaques described above. 
Notably, the relative metabolic values in each brain region also exhibited high stability in 
support of the excellent test-retest reproducibility in the corresponding PRP scores. These 
results agreed with the key brain regions in the PRP (c.f., Fig. 1A) and those reported by 
others in early to advanced PD patients14–18. Moreover, pallidal hypermetabolism has 
consistently been seen in parkinsonian macaques with FDG PET19, 20 and 2-deoxyglucose 
autoradiography21, 22, lending the credence to the pathophysiological models of PD23, 24. In 
this study we did not observe metabolic changes in thalamus and distal regions in the pons 
as reported in our previous study2, owing most likely to the small sample size, species 
difference or both.
In this study the macaques were awake during tracer uptake to reduce the potential effect of 
anesthesia on physiological state of the animal, unlike many other metabolic imaging studies 
in which tracer injection and uptake took place in anesthetized animals19, 20, 25. This novel 
procedure can minimize large variability in local and global brain function due to the varied 
metabolic responses of individual animals to anesthesia. It also ensures that PET imaging 
accurately measures the metabolic activity in conscious animals to match that measured in 
human subjects. This approach can be adopted as part of a viable protocol for PET imaging 
studies in animal models.
Because of the small sample size of the animals in this pilot study we had relied on a graphic 
approach to describe group differences in imaging measures by combining data from 
multiple time points in each animal. Although empirical this pragmatic approach was 
valuable in producing novel findings that were consistent by themselves and in comparison 
to previous reports. Imaging studies in larger samples, with both cross-sectional and 
longitudinal designs, are still needed to confirm these findings and to perform network or 
regional correlations with independent measures of clinical symptoms.
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Fig. 1. 
Reproducibility of a parkinsonism-related pattern (PRP) in non-human primates. A. PRP 
topography in parkinsonian macaques characterized by relatively increased (red-yellow) 
metabolic activity in the putamen, globus pallidus (GP), ventral thalamus, pons, and in the 
medial frontal (MF)/cingulate and sensorimotor (SMC) cortical regions, associated with 
relatively decreased (blue-purple) activity in the parietal-occipital cortex. This pattern was 
originally identified on a whole-brain basis using FDG PET images in the five MPTP-
lesioned and six age-matched healthy rhesus macaques acquired with a HRRT scanner2. B. 
Group discrimination by PRP expressions in the original derivation sample imaged with the 
HRRT PET scanner and a prospective validation sample of nine parkinsonian and five 
normal control scans in cynomolgus macaques obtained with a clinical PET/CT scanner. C: 
Longitudinal changes in metabolic network expression between different time points in the 
prospective validation sample of parkinsonian and control animals. [The overlays represent 
the maps of PRP voxel weights from the network analysis, superimposed on a standard 
macaque MRI brain template11. Error bars in the graph refer to the standard deviations. The 
shaded area denotes the range of two standard deviations above and below the control mean 
in the derivation sample.]
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Fig. 2. 
The distribution of abnormal regional glucose metabolism in non-human primates following 
MPTP administration. A. Mean images of relative cerebral glucose metabolism in normal 
(top) and MPTP-lesioned (bottom) cynomolgus macaques acquired with FDG using a 
clinical PET/CT scanner. The regional distribution of radiotracer uptake was highly 
symmetrical in both normal and parkinsonian macaques. B. Differences in relative regional 
glucose metabolism between the two animal groups comparing the nine parkinsonian and 
five normal control scans. Normalized metabolism increased in the putamen/globus pallidus 
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(GP) and sensorimotor (SMC)/supplementary motor area (SMA) regions, but decreased in 
the bilateral posterior parietal cortex. [The shaded areas in each panel denote the ranges of 
two standard deviations above and below the control mean values in the validation sample.]
Ma et al. Page 12
Mov Disord. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
